How to use the speech recognition tool?

NCT01736592

A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt’s Macular Degeneration

A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt’s Macular Degeneration.

Type: Interventional



Status of the trial: Active, Not recruiting

Orphan Drug Recognition: NA

Inclusion

  • Opening Date: 2014-01-01
  • Closing Date: 2029-01-01

Criteria

Inclusion: Patient must have received a subretinal injection of SAR422459. Patient must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.

Exclusion: Patient did not receive SAR422459 as part of the TDU13583 protocol

More information

Children: No

Adults: Yes

Funder Type: industry

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: